FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burden								
l	hours per response:	0.5							

Г

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Tasker Sybil</u>						2. Issuer Name and Ticker or Trading Symbol Altimmune, Inc. [ ALT ]									5. Relationship of Reporting Person(s (Check all applicable)  Director  Officer (give title			
(Last) (First) (Middle) C/O ALTIMMUNE, INC. 910 CLOPPER ROAD, SUITE 201S						3. Date of Earliest Transaction (Month/Day/Year) 05/21/2018								X Officer (give title below) Other (spec below)  Chief Medical Officer				респу
(Street) GAITHERSBURG MD 20878  (City) (State) (Zip)					-	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					saction	ction 2A. Deemed Execution Date,			Transaction Disposed Code (Instr. 5)			ties Acquire I Of (D) (Ins	ed (A) or	5. Amor Securiti Benefic	nt of 6es Fally (Following (	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
										/	Amount	(0)		Transac (Instr. 3	tion(s)			(1130.4)
		٦	Table II -						uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Options (option to buy)	\$0.445	05/21/2018			A		50,016		(1)	0	5/21/2028	Common Stock, par value \$0.0001	50,016	\$0	50,010	6	D	

## **Explanation of Responses:**

1. Twenty-five percent of the option becomes vested and exercisable on March 1, 2019, and the aggregate unvested remaining portion will vest and become exercisable in equal monthly installments on the first day of each month over the 36-month period starting April 1, 2019.

## Remarks:

/s/ Ori Solomon, Attorney in fact for Sybil Tasker

\*\* Signature of Reporting Person Date

05/23/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.